tapinarof (Vtama) topical cream — prior authorization and renewal criteria
Customize your policy alerts
Sign up for allcareadvantage Policy 114.1 alerts
Get alerted when Policy 114.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and renewal criteria for tapinarof 1% cream (Vtama) for treatment of plaque psoriasis in adults for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for tapinarof (Vtama)
inv-01: Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
If all criteria are met → Approve for 6 months; if any criterion is not met → Deny.
inv-02: Continuation Therapy / Renewal — Renewal criteria
Renewal criteria
If met → Approve for 12 months; if not met → Deny.
This policy limits coverage of tapinarof 1% cream to the FDA‑approved, funded indication of topical treatment of plaque psoriasis in adults. No off‑label indications are specified or covered by this policy.
Initial Therapy
inv-10: Initial therapy — Initial authorization conditions
Initial authorization conditions
Approval length: 6 months.
Continuation / Renewal
inv-11: Renewal — Renewal requirements
Renewal requirements
Approval for 12 months if met; otherwise deny.
Provider Actions and Requirements
Prior authorization required: age, diagnosis, and prior therapy
Prior authorization is required and must document that the member is at least 18 years of age, has a funded diagnosis of plaque psoriasis, has failed or has a contraindication to a formulary high‑potency topical corticosteroid, and has had adequate trials of at least two additional topical agents from the following classes: Vitamin D analogues, calcineurin inhibitors, or retinoids. If all initial criteria are met the request may be approved for 6 months.
- Age ≥18 years
- Funded diagnosis of plaque psoriasis
- Failure or contraindication to a formulary high‑potency topical corticosteroid
- Adequate trials of at least two agents from: Vitamin D analogues, calcineurin inhibitors, or retinoids
Step therapy: required prior trials/failures
Before tapinarof will be approved, the policy requires prior use/failure (or documented contraindication) of a formulary high‑potency topical corticosteroid and an adequate trial of at least two additional topical agent classes (Vitamin D analogue, calcineurin inhibitor, or retinoid).
- Step 1: Failure or contraindication to a formulary high‑potency topical corticosteroid
- Step 2: Adequate trial of at least two additional topical agents from Vitamin D analogues, calcineurin inhibitors, or retinoids
Documentation to support diagnosis and continued benefit
Submit documentation that supports the funded diagnosis of plaque psoriasis at initial request, and for renewal provide documentation of continued clinical benefit (for example, reduction of symptoms).
- Initial request: documentation supporting plaque psoriasis per OHP guidelines
- Renewal request: documentation of continued clinical benefit (e.g., reduction of symptoms)
Denial triggers: missing age, diagnosis, or prior trials
Requests will be denied if any required element is missing: member under 18 years of age, no documentation of plaque psoriasis, no failure or contraindication to a formulary high‑potency topical corticosteroid, or no adequate trials of at least two additional listed topical agents.
- Member < 18 years → Deny
- No documentation to support plaque psoriasis → Deny
- No failure or contraindication to a formulary high‑potency topical corticosteroid → Deny
- No adequate trial of at least two additional agents (Vitamin D analogue, calcineurin inhibitor, or retinoid) → Deny
Step Therapy Requirements
| Step | Required prior trial(s) or contraindication | Notes / Outcome |
|---|---|---|
| 1 | ||
| Failure of (or contraindication to) a formulary high‑potency topical corticosteroid | ||
| Must be met before considering tapinarof; if not met → deny |
Definitions
Background
Tapinarof 1% cream (Vtama) is described in the policy as a first‑in‑class, non‑steroidal aryl hydrocarbon receptor (AhR) modulating agent formulated for topical application. It is applied once daily to affected areas and is intended to reduce the severity of plaque psoriasis. The policy specifies coverage for members 18 years and older with a funded diagnosis of plaque psoriasis and references high‑potency topical corticosteroids as the first‑line comparator and additional topical classes (Vitamin D analogues, calcineurin inhibitors, or retinoids) for step requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.